Zoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone973-822-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.31 billion
Profitability
Miscellaneous
Employees9,200
OptionableOptionable
Zoetis (NYSE:ZTS) Frequently Asked Questions
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis announced a quarterly dividend on Thursday, December 13th. Stockholders of record on Friday, January 18th will be given a dividend of $0.164 per share on Friday, March 1st. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date of this dividend is Thursday, January 17th. This is an increase from Zoetis's previous quarterly dividend of $0.13. View Zoetis' Dividend History.
How will Zoetis' stock buyback program work?
Zoetis announced that its board has initiated a stock repurchase program on Wednesday, December 12th 2018, which allows the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 4.7% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its stock is undervalued.
How were Zoetis' earnings last quarter?
Zoetis Inc (NYSE:ZTS) announced its quarterly earnings results on Thursday, November, 1st. The company reported $0.83 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.77 by $0.06. The firm earned $1.48 billion during the quarter, compared to analyst estimates of $1.46 billion. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The company's revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter last year, the business earned $0.65 EPS. View Zoetis' Earnings History.
When is Zoetis' next earnings date?
How can I listen to Zoetis' earnings call?
Zoetis will be holding an earnings conference call on Thursday, February 14th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has Zoetis issued on next quarter's earnings?
Zoetis issued an update on its FY18 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of $3.08-$3.13 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.08. The company issued revenue guidance of $5.75-$5.80 billion, compared to the consensus revenue estimate of $5.78 billion.Zoetis also updated its FY 2018 guidance to $3.08-3.13 EPS.
What price target have analysts set for ZTS?
16 brokers have issued 12-month price targets for Zoetis' stock. Their forecasts range from $77.00 to $105.00. On average, they anticipate Zoetis' stock price to reach $93.60 in the next year. This suggests a possible upside of 10.7% from the stock's current price. View Analyst Price Targets for Zoetis.
What is the consensus analysts' recommendation for Zoetis?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.
What are Wall Street analysts saying about Zoetis stock?
Here are some recent quotes from research analysts about Zoetis stock:
- 1. According to Zacks Investment Research, "Zoetis continues to maintain momentum on the back of growth from new parasiticide products (Simparicaand Stronghold Plus), vaccines, strong dermatology portfolio and the addition of the Abaxis diagnostics portfolio. The company’s companion animal business has been performing well. The Abaxis acquisition has strengthed the company’s presence in the animal health diagnostics market, a fast-growing portion of the animal health industry which should further boost sales. Moreover, Zoetis five-year collaboration agreement with Regeneron to research the use of latter’s monoclonal antibody therapeutics in animals and discover new veterinary treatments will further diversify the broad portfolio. Shares of Zoetis have outperformed the industry in the last twelve months. However, Zoetis faces stiff competition from companies like Merck Animal Health." (1/6/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and raise our 12-month PT for ZTS shares to $105 from $98. The increase in our PT is driven by multiple expansion. Given the company’s durable business model and the positive outlook for macro factors, we think ZTS’s multiple will hold and upwards earnings revisions should drive shares higher. We think ZTS’s multiple will be supported by: 1) its durable business model, 2) positive outlook for macro factors, and 3) solid execution by management. Upwards earnings revisions could come from: 1) higher-than- anticipated peak sales for new launches, 2) better-than-expected operating margins in 2018+, and 3) M&A." (10/17/2018)
Has Zoetis been receiving favorable news coverage?
Press coverage about ZTS stock has been trending somewhat positive this week, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zoetis earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include AbbVie (ABBV), Eli Lilly And Co (LLY), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN) and ASTELLAS PHARMA/ADR (ALPMY).
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Mr. Juan Ramón Alaix, CEO & Director (Age 67)
- Mr. Glenn C. David, Exec. VP & CFO (Age 46)
- Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 57)
- Mr. Clinton A. Lewis Jr., EVP and Pres of International Ops., Commercial Devel., Global Genetics & Aquatic Health (Age 51)
- Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 47)
Who are Zoetis' major shareholders?
Zoetis' stock is owned by many different of institutional and retail investors. Top institutional investors include Nisa Investment Advisors LLC (0.06%), Gofen & Glossberg LLC IL (0.06%), Copper Rock Capital Partners LLC (0.04%), Boston Advisors LLC (0.03%), DNB Asset Management AS (0.03%) and Neville Rodie & Shaw Inc. (0.03%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.
Which institutional investors are selling Zoetis stock?
ZTS stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Gulf International Bank UK Ltd, Douglas Lane & Associates LLC, Nisa Investment Advisors LLC, KAMES CAPITAL plc, Diligent Investors LLC, Patten & Patten Inc. TN and Louisiana State Employees Retirement System. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.
Which institutional investors are buying Zoetis stock?
ZTS stock was purchased by a variety of institutional investors in the last quarter, including Ferguson Wellman Capital Management Inc., Copper Rock Capital Partners LLC, Park National Corp OH, Navellier & Associates Inc, Meeder Asset Management Inc., Trust Department MB Financial Bank N A, TrimTabs Asset Management LLC and Nippon Life Global Investors Americas Inc.. View Insider Buying and Selling for Zoetis.
How do I buy shares of Zoetis?
Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of ZTS stock can currently be purchased for approximately $84.59.
How big of a company is Zoetis?
Zoetis has a market capitalization of $40.48 billion and generates $5.31 billion in revenue each year. The company earns $864 million in net income (profit) each year or $2.40 on an earnings per share basis. Zoetis employs 9,200 workers across the globe.
What is Zoetis' official website?
How can I contact Zoetis?
Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]
MarketBeat Community Rating for Zoetis (NYSE ZTS)
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
